These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. A meta-analysis of ¹⁸FDG-PET-CT, ¹⁸FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with lung cancer. Qu X; Huang X; Yan W; Wu L; Dai K Eur J Radiol; 2012 May; 81(5):1007-15. PubMed ID: 21354739 [TBL] [Abstract][Full Text] [Related]
24. FDG PET/CT imaging of desmoplastic small round cell tumor: findings at staging, during treatment and at follow-up. Ostermeier A; McCarville MB; Navid F; Snyder SE; Shulkin BL Pediatr Radiol; 2015 Aug; 45(9):1308-15. PubMed ID: 25721584 [TBL] [Abstract][Full Text] [Related]
25. F-18 FDG-PET for detection of osseous metastatic disease and staging, restaging, and monitoring response to therapy of musculoskeletal tumors. Peterson JJ Semin Musculoskelet Radiol; 2007 Sep; 11(3):246-60. PubMed ID: 18260035 [TBL] [Abstract][Full Text] [Related]
26. F-18 FDG PET-CT in patients with recurrent glioma: comparison with contrast enhanced MRI. Santra A; Kumar R; Sharma P; Bal C; Kumar A; Julka PK; Malhotra A Eur J Radiol; 2012 Mar; 81(3):508-13. PubMed ID: 21353420 [TBL] [Abstract][Full Text] [Related]
27. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging. Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400 [TBL] [Abstract][Full Text] [Related]
28. PET and PET/CT in pediatric oncology. Jadvar H; Connolly LP; Fahey FH; Shulkin BL Semin Nucl Med; 2007 Sep; 37(5):316-31. PubMed ID: 17707239 [TBL] [Abstract][Full Text] [Related]
29. Evolving role of 18F-FDG-PET/CT for the body tumor and metastases in pediatrics. Chen Z; Li X; Li F; Ouyang Q; Yu T Eur J Radiol; 2010 Sep; 75(3):329-35. PubMed ID: 20576385 [TBL] [Abstract][Full Text] [Related]
30. [Evaluation of positron emission tomography by using F-18-fluorodeoxyglucose in diagnosis of recurrent colorectal cancer]. Kula Z; Szefer J; Zuchora Z; Romanowicz G; Pietrzak T Pol Merkur Lekarski; 2004; 17 Suppl 1():63-6. PubMed ID: 15603351 [TBL] [Abstract][Full Text] [Related]
31. Recurrent and metastatic breast cancer PET, PET/CT, PET/MRI: FDG and new biomarkers. Gaeta CM; Vercher-Conejero JL; Sher AC; Kohan A; Rubbert C; Avril N Q J Nucl Med Mol Imaging; 2013 Dec; 57(4):352-66. PubMed ID: 24322792 [TBL] [Abstract][Full Text] [Related]
32. Bone and soft-tissue sarcoma: preoperative staging with fluorine 18 fluorodeoxyglucose PET/CT and conventional imaging. Tateishi U; Yamaguchi U; Seki K; Terauchi T; Arai Y; Kim EE Radiology; 2007 Dec; 245(3):839-47. PubMed ID: 18024454 [TBL] [Abstract][Full Text] [Related]
33. PET and PET-CT for evaluation of colorectal carcinoma. Delbeke D; Martin WH Semin Nucl Med; 2004 Jul; 34(3):209-23. PubMed ID: 15202102 [TBL] [Abstract][Full Text] [Related]
34. [Correlation of FDG-PET and MRI/CT with histopathology in primary diagnosis, lymph node staging and diagnosis of recurrency of head and neck cancer]. Pöpperl G; Lang S; Dagdelen O; Jäger L; Tiling R; Hahn K; Tatsch K Rofo; 2002 Jun; 174(6):714-20. PubMed ID: 12063600 [TBL] [Abstract][Full Text] [Related]
35. Value of FDG positron emission tomography in conjunction with MR imaging for evaluating therapy response in patients with musculoskeletal sarcomas. Bredella MA; Caputo GR; Steinbach LS AJR Am J Roentgenol; 2002 Nov; 179(5):1145-50. PubMed ID: 12388489 [TBL] [Abstract][Full Text] [Related]
36. Functional image in soft tissue sarcomas: An update of the indications of Rodríguez-Alfonso B; Simó-Perdigó M; Orcajo Rincón J Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(4):233-243. PubMed ID: 32616457 [TBL] [Abstract][Full Text] [Related]
37. Impact of positron emission tomography/computed tomography in the management of patients with epithelial ovarian carcinoma after treatment. Nasu K; Abe W; Takai N; Tomonari K; Narahara H Arch Gynecol Obstet; 2011 May; 283(5):1121-6. PubMed ID: 20574659 [TBL] [Abstract][Full Text] [Related]
38. Preoperative lymph-node staging of invasive urothelial bladder cancer with 18F-fluorodeoxyglucose positron emission tomography/computed axial tomography and magnetic resonance imaging: correlation with histopathology. Jensen TK; Holt P; Gerke O; Riehmann M; Svolgaard B; Marcussen N; Bouchelouche K Scand J Urol Nephrol; 2011 Mar; 45(2):122-8. PubMed ID: 21231796 [TBL] [Abstract][Full Text] [Related]
39. Multimodality approach of perioperative 18F-FDG PET/CT imaging, intraoperative 18F-FDG handheld gamma probe detection, and intraoperative ultrasound for tumor localization and verification of resection of all sites of hypermetabolic activity in a case of occult recurrent metastatic melanoma. Povoski SP; Hall NC; Martin EW; Walker MJ World J Surg Oncol; 2008 Jan; 6():1. PubMed ID: 18186915 [TBL] [Abstract][Full Text] [Related]